NCT01293383已完成1 期
A Phase 1 Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects. A Single Centre, Prospective, Randomised, Double-blinded, Vehicle-controlled Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Skin irritation
研究概览
简要总结
The purpose of this trial is to to investigate the safety of LEO 90105 compared with its vehicle after multiple administration (twice daily, 5 days) in healthy Japanese male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy Japanese male subjects
- •Aged 20 to 40 years inclusive
- •Subjects without signs of skin irritation (erythema, dryness, roughness or scaling) on the test site
- •Subjects willing to follow the study procedures and complete the study
- •Subjects having understood and signed a written informed consent
- •Subjects without abnormal in physiological test and clinical test in screening, and also judged as possible to participant the study by investigators
排除标准
- •Subjects with Body mass Index (BMI ) (body weight(kg)/height (m)²) outside the range 18-25 kg/m2(18≤BMI<25)
- •Subjects with history of alcohol, chemical or drug abuse
- •Subjects with history of allergic reaction to any content of the study medication
- •Subjects with systemic or cutaneous disease that could in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, psoriasis)
- •Subjects with known sensitivity to any component of any of the formulations being tested
- •Subjects with known hepatic, renal or cardiac disorders
- •Subjects using systemic, locally injected or inhaled corticosteroids within 4 weeks of study start (Day 1)
- •Subjects using systemic vitamin D analogues,vitamin D or calcium supplements within 4 weeks of study start (Day 1)
- •Subjects using any drug (systemic or topical) within 2 weeks of study start (Day 1)
- •Subjects using non-marketed/other investigational products one month prior to or 5 half lives (for those the half life is longer than one month) and during the trial is not permitted
- •Subjects with any abnormality found at medical interview before administration of the test drug, which will affect the clinical study as judged by the investigator
- •Subjects with history of or active photo-induced or photo-aggravated disease (abnormal response to the sun light)
- •Subjects with exposure to excessive or chronic ultraviolet (UV) radiation i.e., sunbathing, tanning salon use, phototherapy) within four weeks prior to study start (Day 1) or planned during the study period
- •Subjects with scars, moles, sunburn, or other blemishes in the test area which would interfere with grading
- •Subjects whose partner wishes to become pregnant but is unwilling to use birth control during the study
- •Subjects with any condition which, in the opinion of the investigator, would place the subject at an unacceptable risk if he participated in the study
- •Subjects with any disease which are contradictions for treatment of the investigation products or for which treatment with the investigation products needs to be carefully considered (Subjects with any of the following conditions present on the area(s) to be treated with study medication: viral (e.g., herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers or wounds)
研究组 & 干预措施
LEO 90105
Other
干预措施: LEO 90105 (Drug)
Vehicle
Other
干预措施: LEO 90105 (Drug)
结局指标
主要结局
Skin irritation
时间窗: 6 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery LesionsIschemiaCoronary Artery DiseaseNCT01909869JW Medical Systems Ltd45
撤回
1 期
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 3.Infection - Other infectious diseasesMalariaACTRN12613000533796CPR Pharma Services24
已完成
1 期
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 1.MalariaACTRN12613000522718CPR Pharma Services73
已完成
1 期
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 2.Infection - Other infectious diseasesMalariaACTRN12613000527763CPR Pharma Services10
进行中（未招募）
不适用
Pilot study for the evaluation of the safety and the feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in patients on stable treatment with two NRTIs + atazanavir/ritonavir with optimal virologic response (AtLaS). - NDHIVMedDRA version: 9.1Level: LLTClassification code 10020443Term: Human immunodeficiency virus syndromeEUCTR2009-011273-32-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI